Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

The pathogenesis of bone erosions in gouty arthritis.

Schlesinger N, Thiele RG.

Ann Rheum Dis. 2010 Nov;69(11):1907-12. doi: 10.1136/ard.2010.128454. Epub 2010 Aug 12.

PMID:
20705636
2.

Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?

Neogi T.

Arthritis Rheum. 2010 Oct;62(10):2845-9. doi: 10.1002/art.27635. No abstract available.

3.

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N.

Arthritis Rheum. 2010 Oct;62(10):3064-76. doi: 10.1002/art.27600.

4.

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E.

Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938. Erratum in: Nature. 2010 Jul 29;466(7306):652.

5.

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases.

Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D.

Ann Rheum Dis. 2009 Dec;68(12):1800-4. doi: 10.1136/ard.2009.115550.

6.

Outcome domains for studies of acute and chronic gout.

Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F.

J Rheumatol. 2009 Oct;36(10):2342-5. doi: 10.3899/jrheum.090370.

PMID:
19820223
7.

The mechanism of osteoclast differentiation induced by IL-1.

Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N.

J Immunol. 2009 Aug 1;183(3):1862-70. doi: 10.4049/jimmunol.0803007. Epub 2009 Jul 8.

8.

Use of canakinumab in the cryopyrin-associated periodic syndrome.

Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN; Canakinumab in CAPS Study Group..

N Engl J Med. 2009 Jun 4;360(23):2416-25. doi: 10.1056/NEJMoa0810787.

9.

Quality of life and disability in patients with treatment-failure gout.

Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B; Gout Natural History Study Group., Sundy JS.

J Rheumatol. 2009 May;36(5):1041-8. doi: 10.3899/jrheum.071229. Epub 2009 Mar 30.

PMID:
19332629
10.

Perceptions of disease and health-related quality of life among patients with gout.

Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A.

Rheumatology (Oxford). 2009 May;48(5):582-6. doi: 10.1093/rheumatology/kep047. Epub 2009 Mar 23. Erratum in: Rheumatology (Oxford). 2009 Nov;48(11):1468.

11.

Quality of life and quality of care for patients with gout.

Singh JA.

Curr Rheumatol Rep. 2009 Apr;11(2):154-60. Review.

12.

Role of interleukin-1beta during pain and inflammation.

Ren K, Torres R.

Brain Res Rev. 2009 Apr;60(1):57-64. doi: 10.1016/j.brainresrev.2008.12.020. Epub 2008 Dec 31. Review.

13.

Developments in the scientific and clinical understanding of gout.

So A.

Arthritis Res Ther. 2008;10(5):221. doi: 10.1186/ar2509. Epub 2008 Oct 10. Review.

14.

Clinical manifestations of hyperuricemia and gout.

Mandell BF.

Cleve Clin J Med. 2008 Jul;75 Suppl 5:S5-8. Review.

PMID:
18822469
15.

Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.

Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, McQueen FM.

Ann Rheum Dis. 2009 Aug;68(8):1290-5. doi: 10.1136/ard.2008.094201. Epub 2008 Aug 15.

PMID:
18708415
16.

Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.

Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, Mikecz K, Glant TT.

Arthritis Rheum. 2008 Aug;58(8):2397-408. doi: 10.1002/art.23653.

17.

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.

Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C.

Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140-6736(08)60799-0.

PMID:
18514729
18.

Long-term cardiovascular mortality among middle-aged men with gout.

Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group..

Arch Intern Med. 2008 May 26;168(10):1104-10. doi: 10.1001/archinte.168.10.1104.

PMID:
18504339
19.

The disutility of chronic gout.

Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, Tsevat J.

Qual Life Res. 2008 Jun;17(5):815-22. doi: 10.1007/s11136-008-9355-0. Epub 2008 May 24.

PMID:
18500578
20.

Supplemental Content

Support Center